Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Prospective Trial Evaluating the Efficacy of the antiCD38 Monoclonal Antibody Isatuximab in the Treatment of PCRA by Major ABO Mismatch After Allogeneic Hematopoietic Stem Cell Transplantation

NCT05559827 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT05559827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05559827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Prospective Trial Evaluating the Efficacy of the antiCD38 Monoclonal Antibody Isatuximab in the Treatment of PCRA by Major ABO Mismatch After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2022
Completion date
October 31, 2026
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

immunological pure red cell aplasia